Browse > Article
http://dx.doi.org/10.3904/kjm.2013.84.1.111

A Case Report of Papillary Thyroid Carcinoma Presenting as Elevated Serum CA 19-9  

Jang, Eun Kyung (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Choi, Yun Mi (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Kim, Ho Cheol (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Kim, Tae Yong (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Hong, Suck Joon (Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine)
Shong, Young Kee (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Kim, Won Bae (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Publication Information
The Korean Journal of Medicine / v.84, no.1, 2013 , pp. 111-115 More about this Journal
Abstract
A 47-year-old man had elevated serum CA 19-9 after a routine health check-up. He had normal CA 19-9 levels during the preceding 8 years on annual heath checks. Imaging studies for pancreatic or biliary tract diseases revealed no abnormalities. A huge hypermetablic lesion was found in the right lobe of the thyroid on $^{18}F$-fluorodeoxyglucose positron emission tomography/computed tomography. We performed a fine needle aspiration of the thyroid nodule. He was diagnosed with papillary thyroid carcinoma and underwent a total thyroidectomy with a modified radical neck dissection. Serum CA 19-9 level decreased to the normal range after surgery. Although there have been few reports of patients with elevated serum CA 19-9 levels due to papillary thyroid carcinoma, this is the first report showing such an association in Korea. Thyroid cancer should be considered when the causes of elevated serum CA 19-9 are unclear.
Keywords
Serum CA 19-9; Papillary thyroid carcinoma;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Park JK, Yoon YB, Kim YT, et al. Survival and prognostic factors of unresectable pancreatic cancer. Korean J Med 2007;72:151-161.
2 Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007;33:266-270.   DOI   ScienceOn
3 Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H. Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res 1982;42:4820-4823.
4 Matsuura B, Taniguchi Y, Nakanishi K, et al. Serum levels and thyroid tissue expression of CA50 and CA 19-9 in patients with thyroid tumor. Endocrinol Jpn 1991;38:565-571.   DOI
5 Ogawa M, Hori H, Hirayama M, et al. Anaplastic transformation from papillary thyroid carcinoma with increased serum CA19-9. Pediatr Blood Cancer 2005;45:64-67.   DOI   ScienceOn
6 Vierbuchen M, Schroder S, Uhlenbruck G, Ortmann M, Fischer R. CA 50 and CA 19-9 antigen expression in normal, hyperplastic, and neoplastic thyroid tissue. Lab Invest 1989;60:726-732.
7 Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004;19:182-186.   DOI   ScienceOn
8 Safi F, Roscher R, Beger HG. Tumor markers in pancreatic cancer: sensitivity and specificity of CA 19-9. Hepatogastroenterology 1989;36:419-423.
9 Larena A, Vierbuchen M, Fischer R. Blood group antigen expression in malignant tumors of the thyroid: a parallel between medullary and nonmedullary carcinomas. Langenbecks Arch Chir 1995;380:269-272.